Back to Health

What Is Efavirenz and What Is It For?

What Is Efavirenz and What Is It For?
Bareback Guide 18 May 2026

Efavirenz is a non-nucleoside reverse transcriptase inhibitor that was, for well over a decade, the most widely used antiretroviral in the world. It is highly effective and has been largely replaced in UK first-line treatment because of its effects on the central nervous system.

What kind of drug is it?

A non-nucleoside, which targets the same enzyme as the nucleoside analogues by an entirely different route. Rather than posing as a building block, it disables the enzyme directly.

How does it work?

HIV must convert its RNA genome into DNA using reverse transcriptase. Efavirenz binds to a pocket on the enzyme and distorts its structure so that the conversion can no longer be performed properly.

Why was it so widely used?

Because it was potent, once daily, available in a single tablet with a backbone, and cheap once generic. For treatment programmes serving millions of people, that combination was transformative.

What is it used for?

HIV treatment as part of a combination. In the UK it is now mostly encountered in people who have taken it successfully for years rather than in people starting. It remains important in parts of the world where cost and supply considerations differ.

Why was it superseded?

Not for lack of effectiveness. Comparative trials consistently found similar viral suppression against newer drugs alongside substantially higher rates of neuropsychiatric side effects and discontinuation. People stopped taking it, which is what drove the change.

What are those effects?

Vivid or disturbing dreams, dizziness, difficulty concentrating, a sense of detachment, insomnia and mood changes. Most pronounced in the first weeks and often improving afterwards, though for a substantial minority they persist.

Does it need a booster?

No. It maintains useful levels for a full day on its own. It does, however, induce liver enzymes, which creates a different set of interaction problems running in the opposite direction to boosters.

What is its resistance barrier?

Relatively low, as with older drugs in this class. A single mutation can confer high-level resistance, which means missed doses carry more risk than with integrase inhibitors or boosted protease inhibitors.

Does it cover hepatitis B?

Efavirenz itself does not. Combinations containing it usually include emtricitabine and tenofovir, which do. Hepatitis B status is checked before any regimen is chosen.

Why does the dose matter?

Because a reduced 400mg dose was studied and found effective with fewer side effects, and is used in some settings. The standard 600mg dose remains more common, and this is worth asking about if side effects are the problem.

Does everyone respond the same way?

No, and this is genetically determined in part. Variations in the enzyme that clears efavirenz mean some people reach much higher levels than others at the same dose, which predicts who suffers most from the side effects.

How long has it been available?

Since the late 1990s, so there is over twenty-five years of experience with it. Its properties are exhaustively characterised, which is one reason it remains a useful reference point in research.

Should you switch if you are on it?

Not automatically. If you have taken it for years without difficulty, there is no urgent reason to change. If you are struggling with sleep, mood or cholesterol, there is.

Where does it sit against the alternatives?

Behind integrase inhibitors and doravirine on tolerability, and equal on eventual effectiveness. The fit depends on what you have tolerated and what else is available to you.

What happens when you start it?

Baseline blood tests first, covering kidney and liver function, lipids, viral load and CD4 count, plus hepatitis status and a resistance test. A follow-up appointment usually comes a few weeks later to check tolerability and early response.

Will you have to take it forever?

HIV treatment continues indefinitely, and what you take changes over the years. Being on efavirenz now does not commit you to it permanently, and most people are on something different a decade later as options improve.

Does it stop you passing HIV on?

Any regimen that achieves and sustains an undetectable viral load does, including this one. Once suppression is sustained, HIV is not transmitted sexually. That is a property of effective treatment rather than of efavirenz specifically.